{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-26-014504","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2026-11-17T21:30:32+00:00","discovered_at":"2026-11-17T21:33:03.446314+00:00","generated_at":"2026-11-17T21:33:14.224610+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.62,"calibrated_materiality_score":0.62,"confidence":"high","headline":"Alzamend pauses AL001 bipolar trial after FDA rejects enrollment-criteria change; MGH terminates BD SOW","bullets":["FDA wrote on Oct 15, 2026 that the AL001 bipolar trial design did not appear adequate and well-controlled enough to support an NDA.","Alzamend paused the BD Clinical Trial on Oct 21, 2026 after MGH said co-morbidity exclusions (diabetes, cardiovascular disease, anxiety) hampered enrollment.","MGH terminated the bipolar statement of work on Nov 11, 2026 and will refund about $25,000 in unused funds; the Healthy SOW is unaffected.","Company will seek a Type B FDA meeting on a revised plan expected to drop Phase II and move directly to a Phase III efficacy/safety trial in bipolar; feedback targeted by end of Q2 2027.","Final clinical study report and results for the Healthy Patient Clinical Trial, initiated May 2025 and completed Nov 2025, are expected in December 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-26-014504","json":"https://secwatch.observer/filing/0001214659-26-014504.json","markdown":"https://secwatch.observer/filing/0001214659-26-014504.md","text":"https://secwatch.observer/filing/0001214659-26-014504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465926014504/0001214659-26-014504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465926014504/o11172648k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-17T21:33:14.224610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}